CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

Core Insights - CAMP4 Therapeutics Corporation is advancing its CMP-002 program for SYNGAP1-related disorders, with plans to initiate a Phase 1/2 clinical trial as early as the second half of 2026 following the initiation of Good Laboratory Practice (GLP) toxicology studies [1][2][6] - The company has completed the analysis of the CMP-001 Phase 1 clinical trial, which showed favorable safety and pharmacokinetics, and is seeking partnerships for further development of CMP-001, aimed at treating urea cycle disorders [2][5][6] Financial Highlights - As of September 30, 2025, the company reported cash, cash equivalents, and marketable securities totaling $75.3 million, an increase from $39.1 million as of June 30, 2025 [8] - Research and development expenses for Q3 2025 were $9.4 million, slightly down from $9.7 million in Q3 2024, primarily due to increased clinical and preclinical study costs [8] - General and administrative expenses rose to $4.6 million in Q3 2025 from $3.8 million in Q3 2024, driven by higher personnel-related and overhead costs [9] - The net loss for Q3 2025 was $15.1 million, compared to a net loss of $13.5 million in Q3 2024 [9] Program Developments - The CMP-002 program is focused on SYNGAP1-related disorders, with the company having initiated GLP toxicology studies to support a planned clinical trial application [1][6] - The CMP-001 program, targeting urea cycle disorders, has shown promising results in safety and pharmacokinetics from the Phase 1 SAD/MAD study, with no serious adverse events reported [5][6] Strategic Decisions - The company has made a strategic decision to pursue partnerships for the further development of CMP-001, recognizing its potential as a first disease-modifying therapy for prevalent urea cycle disorders [2][6] - CAMP4 continues to explore new candidates for both in-house development and potential partnerships to enhance its pipeline of disease-modifying medicines [2]